NCT00109993View on ClinicalTrials.gov

Campath-1H + FK506 and Methylprednisolone for GVHD

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

June 30, 2006

Study Completion Date

May 31, 2007

Conditions
Breast CancerChronic Myeloproliferative DisordersGestational Trophoblastic TumorGraft Versus Host DiseaseLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative DiseasesNeuroblastomaOvarian CancerTesticular Germ Cell Tumor
Interventions
BIOLOGICAL

alemtuzumab

alemtuzumab IV over 2 hours on days 4-6, 18, and 32

DRUG

methylprednisolone

methylprednisolone IV on days 1-3 and then orally or IV on days 4-14

DRUG

tacrolimus

tacrolimus IV continuously on days 1-7 and then orally once or twice daily on days 8-180, followed by a taper in the absence of chronic graft-vs-host disease

Trial Locations (6)

10029

Mt. Sinai Medical Center, New York

15224

Western Pennsylvania Hospital, Pittsburgh

44195

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

78229

Texas Transplant Institute, San Antonio

97239

Oregon Health Sciences University, Portland

44106-7284

Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Case Comprehensive Cancer Center

OTHER

NCT00109993 - Campath-1H + FK506 and Methylprednisolone for GVHD | Biotech Hunter | Biotech Hunter